Brain-Reactive Autoantibodies Prevalent in Human Sera Increase Intraneuronal Amyloid-β1-42 Deposition
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Previous studies have reported immunoglobulin-positive neurons in Alzheimer's disease (AD) brains, an observation indicative of blood-brain barrier (BBB) breakdown. Recently, we demonstrated the nearly ubiquitous presence of brain-reactive autoantibodies in human sera. The significance of these observations to AD pathology is unknown. Here, we show that IgG-immunopositive neurons are abundant in brain regions exhibiting AD pathology, including intraneuronal amyloid-β(42) (Aβ(42)) and amyloid plaques, and confirm by western analysis that brain-reactive autoantibodies are nearly ubiquitous in human serum. To investigate a possible interrelationship between neuronal antibody binding and Aβ pathology, we tested the effects of human serum autoantibodies on the intraneuronal deposition of soluble Aβ(42) peptide in adult mouse neurons in vitro (organotypic brain slice cultures). Binding of human autoantibodies to mouse neurons dramatically increased the rate and extent of intraneuronal Aβ(42) accumulation in the mouse cerebral cortex and hippocampus. Additionally, individual sera exhibited variable potency related to their capacity to enhance intraneuronal Aβ(42) peptide accumulation and immunolabel neurons in AD brain sections. Replacement of human sera with antibodies targeting abundant neuronal surface proteins resulted in a comparable enhancement of Aβ(42) accumulation in mouse neurons. Overall, results suggest that brain-reactive autoantibodies are ubiquitous in the blood and that a defective BBB allows these antibodies to access the brain interstitium, bind to neuronal surfaces and enhance intraneuronal deposition of Aβ(42) in AD brains. Thus, in the context of BBB compromise, brain-reactive autoantibodies may be an important risk factor for the initiation and/or progression of AD as well as other neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159
Cerebral microvascular pathology in aging and Alzheimer's disease
Farkas, E., & Luiten, P. G. M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00068-x · Cited by 1,102 · cited 1×
“Certainly, vascular pathologies within the brain, such as cerebrovascular amyloidosis, would be expected to have a negative influence on BBB integrity [15, 66, 67].”
Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment
Scheff, S. W., Price, D. A., Schmitt, F. A., & Mufson, E. J. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.012 · Cited by 1,017
Intraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease
Oddo, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.012 · Cited by 980 · cited 1×
“A accumulation within neurons has been shown to occur before the appearance of amyloid plaques in both human and transgenic mouse brains, and there is evidence that the eventual death and lysis of A 42overburdened neurons can lead to the appearance of amyloid plaques [6, 8, 17, 72, 73].”
Takahashi, R. H., Milner, T. A., Li, F., Nam, E. E., Edgar, M. A., Yamaguchi, H., Beal, M. F., Xu, H., Greengard, P., & Gouras, G. K. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64463-x · Cited by 706
Synaptic loss in Alzheimer's disease and other dementias
Hamos, J. E., DeGennaro, L. J., & Drachman, D. A. (1989) · Neurology · doi:10.1212/wnl.39.3.355 · Cited by 432
Astrocytes accumulate Aβ42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains
Nagele, R. G., D’Andrea, M. R., Lee, H., Venkataraman, V., & Wang, H.-Y. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02361-8 · Cited by 416
Self-citationD'Andrea, M. R., Nagele, R. G., Wang, H., Peterson, P. A., & Lee, D. H. S. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01082.x · Cited by 390
Self-citationCerebral amyloid angiopathy and its relationship to Alzheimer’s disease
Thal, D. R., Griffin, W. S. T., de Vos, R. A. I., & Ghebremedhin, E. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0366-2 · Cited by 372
Losing your nerves? Maybe it's the antibodies
Diamond, B., Huerta, P. T., Mina-Osorio, P., Kowal, C., & Volpe, B. T. (2009) · Nature Reviews Immunology · doi:10.1038/nri2529 · Cited by 247
Lanz, T. A., Carter, D. B., & Merchant, K. M. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00079-2 · Cited by 227
The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease
Bailey, T. L., Rivara, C. B., Rocher, A. B., & Hof, P. R. (2004) · Neurological Research · doi:10.1179/016164104225016272 · Cited by 213 · cited 1×
“Certainly, vascular pathologies within the brain, such as cerebrovascular amyloidosis, would be expected to have a negative influence on BBB integrity [15, 66, 67].”
Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease
Lennon, V. A., Ermilov, L. G., Szurszewski, J. H., & Vernino, S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17429 · Cited by 178
McKeon, A., Lennon, V. A., Lachance, D. H., Fealey, R. D., & Pittock, S. J. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.78 · Cited by 168
Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy
Vernino, S., Hopkins, S., & Wang, Z. (2009) · Autonomic Neuroscience · doi:10.1016/j.autneu.2008.09.005 · Cited by 123
Fuentealba, R. A., Liu, Q., Zhang, J., Kanekiyo, T., Hu, X., Lee, J.-M., LaDu, M. J., & Bu, G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011884 · Cited by 116
Interleukins, Inflammation, and Mechanisms of Alzheimer's Disease
Weisman, D., Hakimian, E., & Ho, G. J. (2006) · Vitamins & Hormones · doi:10.1016/s0083-6729(06)74020-1 · Cited by 95
Cited by
Nagele, E. P., Han, M., Acharya, N. K., DeMarshall, C., Kosciuk, M. C., & Nagele, R. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060726 · Cited by 309
Self-citationXiang, Y., Bu, X.-L., Liu, Y.-H., Zhu, C., Shen, L.-L., Jiao, S.-S., Zhu, X.-Y., Giunta, B., Tan, J., Song, W.-H., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1477-1 · Cited by 277
A study on the association between infectious burden and Alzheimer's disease
Bu, X. ‐., Yao, X. ‐., Jiao, S. ‐., Zeng, F., Liu, Y. ‐., Xiang, Y., Liang, C. ‐., Wang, Q. ‐., Wang, X., Cao, H. ‐., et al. (2015) · European Journal of Neurology · doi:10.1111/ene.12477 · Cited by 273
(2012) · doi:10.1038/nrneurol.2012.118 · Cited by 122
Acharya, N. K., Levin, E. C., Clifford, P. M., Han, M., Tourtellotte, R., Chamberlain, D., Pollaro, M., Coretti, N. J., Kosciuk, M. C., Nagele, E. P., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122254 · Cited by 121
Self-citation
Metadata
- Authors
- Nagele, R. G., Clifford, P. M., Siu, G., Levin, E. C., Acharya, N. K., Han, M., Kosciuk, M. C., Venkataraman, V., Zavareh, S., Zarrabi, S., Kinsler, K., Thaker, N. G., Nagele, E. P., Dash, J., Wang, H. Y., & Levitas, A.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2011-08-05
- Volume
- 25
- Issue
- 4
- Pages
- 605-622
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2153829642
- Cited by
- 65
- References
- 21
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.